Florian Heitz - Gynecology

Author Information

Florian Heitz is affiliated with the Department of Gynecology and Gynecologic Oncology at Evangelische Kliniken Essen-Mitte (KEM) in Essen, Germany. He is a specialist in the field of Gynecology, particularly focusing on ovarian cancer.

Research Contributions

Florian Heitz has made significant contributions to the field of Gynecology, particularly in ovarian cancer research. His work includes the development and validation of prognostic tools, risk modeling, and innovative treatment approaches. He has published extensively on topics such as cell-free tumor DNA, polygenic risk modeling, and the impact of co-medication on survival in ovarian cancer patients. His research aims to improve diagnostic and treatment strategies for advanced high-grade serous ovarian cancer, among other related topics.

Aliases

F Heitz, F. Heitz, Florian Heitz

Publication and Citation Metrics

Metric	Value
Citation Count	6912
H-index	42
Paper Count	284

Publications:

Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer

DOI: 10.1371/journal.pone.0262770

Year: 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience

DOI: 10.1016/j.gore.2022.100939

Year: 2022

Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)

DOI: 10.1038/s41416-021-01662-w

Year: 2021

241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators

DOI: 10.1136/ijgc-2021-esgo.366

Year: 2021

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring

DOI: 10.3390/cancers14010168

Year: 2021

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer

DOI: 10.1158/1055-9965.EPI-20-1817

Year: 2021

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

DOI: 10.1016/j.xhgg.2021.100042

Year: 2021

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

DOI: 10.1016/j.annonc.2021.08.2110

Year: 2021

What are the Alternatives to Hysteroscopy?

What Qualifies Someone to be an Expert Witness in Gynecology?

Why Are On Call Shifts Important in Gynecology?

What are UNFPA’s Key Programs in Gynecology?

What is the Vaginal Area?

What are the Risks for the Mother and Baby?

What is the Cochrane Library?

8. How is Pelvic Inflammatory Disease (PID) treated?

What are some key innovations in gynecological surgical instruments?

How Can Education and Awareness Help?

Partnered Content Networks

Relevant Topics